Palatin Technologies (PTN) Operating Expenses (2010 - 2026)
Palatin Technologies' (PTN) quarterly Operating Expenses came in at $5.5 million in Q1 2026, up 14.3% YoY from $4.8 million in Q1 2025, and down 26.1% on a QoQ basis from $7.4 million in Q4 2025.
Palatin Technologies (PTN) Operating Expenses (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 17 years of Operating Expenses data on file, last reported at $5.5 million in Q1 2026.
- Quarterly Operating Expenses rose 14.3% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.4 million (down 18.75% YoY) and the FY2025 annual result came in at $17.5 million, down 35.3% from the prior year.
- Operating Expenses eased to $5.5 million in Q1 2026, from $7.4 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $13.9 million in Q2 2022 to a low of $860968.0 in Q4 2023.
- A 5-year average of $7.1 million and a median of $7.8 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2023 — Operating Expenses slumped 86.98% — and 2024, when it jumped 203.3%.
- Tracing PTN's Operating Expenses over 5 years: stood at $6.6 million in 2022, then tumbled by 86.98% to $860968.0 in 2023, then jumped by 203.3% to $2.6 million in 2024, then surged by 185.09% to $7.4 million in 2025, then fell by 26.1% to $5.5 million in 2026.
- The last three Operating Expenses figures came in at $5.5 million (Q1 2026), $7.4 million (Q4 2025), and $4.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Palatin Technologies | 40.86 Mn | 40.86 Mn | - | 5.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.50 Mn |
| Dec 31, 2025 | 7.44 Mn |
| Sep 30, 2025 | 4.19 Mn |
| Jun 30, 2025 | 2.27 Mn |
| Mar 31, 2025 | 4.81 Mn |
| Dec 31, 2024 | 2.61 Mn |
| Sep 30, 2024 | 7.76 Mn |
| Jun 30, 2024 | 8.69 Mn |
| Mar 31, 2024 | 9.22 Mn |
| Dec 31, 2023 | 860,968.00 |
| Sep 30, 2023 | 8.21 Mn |
| Jun 30, 2023 | 12.58 Mn |
| Mar 31, 2023 | 8.50 Mn |
| Dec 31, 2022 | 6.61 Mn |
| Sep 30, 2022 | 9.62 Mn |
| Jun 30, 2022 | 13.87 Mn |
| Mar 31, 2022 | 8.04 Mn |
| Dec 31, 2021 | 8.77 Mn |
| Sep 30, 2021 | 7.38 Mn |
| Jun 30, 2021 | 13.88 Mn |